What is Sano Genetics?
Sano Genetics is a UK-based platform dedicated to advancing research in personalized medicine. Established by three Ph.D. students from the University of Cambridge—Patrick Short, Charlotte Guzzo, and William Jones—the platform offers a free-to-use service. It empowers users to upload their existing genetic and medical data, facilitating matches with relevant research studies and clinical trials. This initiative is crucial for powering the future of personalized medicine by connecting individuals with opportunities to contribute to and benefit from cutting-edge medical advancements.
How much funding has Sano Genetics raised?
Sano Genetics has raised a total of $25.8M across 3 funding rounds:
Angel/Seed
$3.4M
Series A
$11M
Other Financing Round
$11.4M
Angel/Seed (2021): $3.4M with participation from Episode 1 Ventures LLP, Cambridge Enterprise, January Ventures, and Seedcamp Ltd
Series A (2022): $11M led by MMC Ventures
Other Financing Round (2024): $11.4M supported by Plural
Key Investors in Sano Genetics
Plural
Plural is a strategy consultancy that aids businesses in achieving transformational growth, advising major corporations and private equity investors globally across various sectors.
Episode 1 Ventures LLP
Episode 1 Ventures is a London-based venture capital firm that invests in UK software-driven businesses with high growth potential, typically providing early-stage institutional investment.
MMC Ventures
MMC Ventures is an investment firm that backs and scales transformative technology companies from the Seed and Series A stages, with a focus on deep understanding of technology and business models.
What's next for Sano Genetics?
The recent major strategic investment signals a pivotal growth phase for Sano Genetics. This capital will likely be deployed to scale its research platform, expand its user base, and forge new partnerships within the biotechnology and healthcare industries. The company's focus on personalized medicine research positions it to capitalize on the increasing demand for tailored health solutions and data-driven medical discovery. Future developments may include enhanced data analytics capabilities and broader integration with clinical trial networks, further solidifying its role in the evolving landscape of precision health.
See full Sano Genetics company page
